Jazz Pharmaceuticals plc is an Ireland‑domiciled, global biopharmaceutical company focused on neuroscience and oncology. The company develops, manufactures, and commercializes medicines addressing serious, often rare conditions in areas such as sleep medicine, epilepsy, and hematologic and solid tumors.
Its portfolio includes therapies such as Xywav/Xyrem for narcolepsy; cannabidiol (Epidiolex) for certain rare epilepsies; Rylaze (recombinant asparaginase) for acute lymphoblastic leukemia; Vyxeos (CPX‑351) liposomal for acute myeloid leukemia; Zepzelca (lurbinectedin) for small cell lung cancer; and Defitelio (defibrotide) for hepatic veno‑occlusive disease. Jazz also advances a pipeline spanning additional neuroscience and oncology indications, leveraging small molecules, recombinant enzymes, liposomal formulations, and other innovative modalities.
Jazz operates across North America and Europe with research, clinical development, regulatory, manufacturing, and commercial capabilities, supplying products to patients in multiple global markets in compliance with international regulatory standards.